Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.

Assess the effectiveness of combined therapy Actair® plus Xolair compared to monotherapy with Actair® or Xolair® or standard symptomatic therapy in patients with mild or moderate allergic asthma to HDM.

Treatment duration: 24 months Follow-up duration:12 months Total duration: 36 months (not including screening and randomization period) May 2024 - March 2028 Consisting of a 4 to 5 months screening phase (with 1 month observation period prior to randomization) a treatment phase of 24 months and post-treatment follow-up phase 12 months

Inclusion Criteria:• >18 years old

• A total IgE between 30-700 IU/mL
• Moderate asthma with perennial symptoms confirmed as HDM-driven asthma based on medical history and positive nasal provocation tests, partially controlled asthma;
• FEV1 >70% at baseline;
• Positive skin prick test results for D. pteronyssinus, D. farinae

Exclusion Criteria:

• Sensitisation to other allergens with clinical signs not related to HDM
• Uncontrolled asthma,
• Other serious diseases or chronic unstable diseases
• Allergen immunotherapy during the past 5 years
• Contraindicating allergen immunotherapy and omalizumab treatment.

by computer database registration